Skip navigation
Browsing by Author Mehra, N.
Showing results 1 to 2 of 2
| Preview | Issue Date | Title / Name | Author(s) |
| 8-Aug-2025 | Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer | Mehra, N.; Antonarakis, E. S.; Park, S. H.; Goh, J. C.; McDermott, R.; Gonzalez, N. S.; Fong, P. C.; Griel, R.; De Santis, M.; Yanez, P. E.; Huang, Y. H.; Begbie, S. D.; Rey, F.; Kramer, G.; Suzuki, H.; Saretsky, T. L.; Ghate, S. R.; Cui, Y.; Hosius, C.; Yu, E. Y.; Begbie, Stephen | |
| Aug-2023 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial | Antonarakis, E.; Park, S. H.; Goh, J. C.; Shin, S. J.; Lee, J. L.; Mehra, N.; Dermott, R.; Sala-Gonzalez, N.; Fong, P. C.; Greil, R.; Retz, M.; Sade, J. P.; Yanez, P.; Huang, Y.; Begbie, S. D.; et. al; Begbie, Stephen | |
